Sensex

Nifty

USDINR

GBPINR

EURINR

BSE
NSE

Friday, 14 November 2025 12:00 AM EOD	Asian-Paints2906.40	Hind-Unilever2426.75	ITC407.85	Trent4389.40	Larsen-and-Toubro3995.30	M-and-M3694.05	Reliance-Industr1518.85	Tata-Motors-PVeh391.60	Tata-Steel174.15	Titan-Company3824.40	SBI967.35	Bharat-Electron426.95	Kotak-Mah-Bank2075.15	Infosys1502.50	Bajaj-Finance1018.20	Sun-PharmaInds1756.40	HDFC-Bank988.85	TCS3105.00	ICICI-Bank1371.90	Power-Grid-Corpn271.30	Maruti-Suzuki15678.55	Axis-Bank1242.75	HCL-Technologies1593.95	NTPC328.45	Bharti-Airtel2098.70	Tech-Mahindra1438.25	Adani-Ports1511.70	UltraTech-Cem11863.60	Bajaj-Finserv2064.00	Eternal-Ltd303.55	Tata-Motors321.65
15 mins delay SENSEX 84,562.78 [84.11]	27.30 0.95%	19.45 0.81%	2.10 0.52%	67.45 1.56%	-6.65 -0.17%	-5.15 -0.14%	8.25 0.55%	-6.45 -1.62%	-2.45 -1.39%	-12.90 -0.34%	12.80 1.34%	7.15 1.70%	0.50 0.02%	-39.85 -2.58%	13.05 1.30%	20.60 1.19%	2.05 0.21%	-0.70 -0.02%	-14.05 -1.01%	1.35 0.50%	-76.95 -0.49%	17.85 1.46%	-4.55 -0.28%	1.20 0.37%	6.55 0.31%	-12.55 -0.87%	13.90 0.93%	-75.60 -0.63%	7.95 0.39%	5.85 1.97%	1.40 0.44%

Hot Pursuit

Scrips, which has significant changes during the market hours.

Alembic Pharma gets US FDA approval for angina treatment drug Diltiazem

15-Nov-25 09:45Hrs IST

The approved ANDA is therapeutically equivalent to the reference listed drug (RLD), Cardizem Tablets of Bausch Health US, LLC.

Diltiazem hydrochloride tablets are indicated for the management of chronic stable angina and angina due to coronary artery spasm.

Alembic has a cumulative total of 230 ANDA approvals (210 final approvals and 20 tentative approvals) from USFDA.

Alembic Pharmaceuticals is a vertically integrated research and development pharmaceutical company. It manufactures and markets generic pharmaceutical products all over the world. Its research and manufacturing facilities are approved by regulatory authorities of many developed countries, including the USFDA.

The company's consolidated net profit jumped 20.40% to Rs 184.71 crore in Q2 FY26, compared to Rs 153.41 crore posted in Q2 FY25. Revenue from operations grew 15.90% year on year (YoY) to Rs 1,910.15 crore in the quarter ended 30 September 2025.

The scrip had fallen 1.58% to end at Rs 902.80 on the BSE yesterday.

Powered by Capital Market - Live News

Attention Investor :

"Prevent unauthorised transactions in your account ; Update your mobile numbers/email IDs with Us. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day” - Issued in the interest of Investors"

"KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary."

"No need to issue cheques by investors while subscribing to Equity IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

A Muthoot M George Enterprise